This non-interventional, epidemiological study assesses long-term outcomes in subjects receiving immunoglobulins (IgG) for any treatment purpose, irrespective of the regimen prescribed by the treating physician, under routine clinical conditions in Germany. Long-term outcome data are collected on patient characteristics in the various indications, drug utilization of intravenous and subcutaneous IgG (e.g. treatment and dosing patterns), effectiveness (i.e. number of infections), tolerability, health related quality of life, and economic variables (number of hospitalizations, sick-leave days etc.) with the possibility to estimate direct costs.
In view of the broad range of indications in immunodeficiency and immunomodulation, it is of interest to document the use of IgG under the conditions of everyday practice and to analyze the endpoints (outcomes). A prospective cohort study such as this is an important evidence source for such rare diseases as those mentioned above. The aim of this outcome study is to fill the gap of the lack of long-term data in these rare diseases treated with IgG.
Study Type
OBSERVATIONAL
Enrollment
685
Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.
Klinik für Neurologie, St. Josefs-Hospital der Ruhr-Univ.
Bochum, Germany
Praxis für Hämatologie und Internistische Onkologie
Cologne, Germany
Institute for Clinical Pharmacology
Dresden, Germany
Klinik für Neurologie, Medizinische Hochschule
Hanover, Germany
Klinik für Pädiatrische Pneumologie, Allergologie und Neonatologie, Medizinische Hochschule (MHH).
Hanover, Germany
Fachbereich Pädiatrische Rheumatologie, Immunologie und Infektiologie am Klinikum St. Georg gGmbH Leipzig, Akademisches Lehrkrankenhaus der Universität
Leipzig, Germany
Mannheimer Onkologie-Praxis
Mannheim, Germany
Immunoglobulin IgG dosage
Dosage of immunoglobulins (IgG); frequency of IgG administrations; days of treatment with IgG; duration of infusion of IgG.
Time frame: up to 54 months
Infection rate
For immunodeficiencies (primary PID and secondary SID): frequency of infections; degree of severity of infections (SBIs); duration of antibiotic treatment; necessity of antibiotic treatment.
Time frame: up to 54 months
Neurological and muscular function (for neurological auto-immune diseases only)
Grip strength (dynamometer) Electrophysiology (EMG, ENG); Inflammatory Neuropathy Cause and Treatment (INCAT) disability score; EDSS, annual relapse rate; Myasthenia Score.
Time frame: up to 54 months
Duration of manifest auto-immune disease within the follow-up period(for neurological auto-immune diseases only).
Time frame: up to 54 months
Health-related quality of life
Time frame: up to 54 months
Pharmacoeconomic parameters
Number of sick-leave days Number of medical visits Days of hospitalisation due to infections or due to disability or loss of function Degree of disability
Time frame: up to 54 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.